Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05756322 · ClinicalTrials.gov registry record · Phase 1
The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
A Phase 1 study of Relapsed or Resistant Acute Leukaemias, sponsored by Lin BioScience.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 14
- Study locations
NCT05756322 is a Phase 1 study of Relapsed or Resistant Acute Leukaemias that is actively recruiting participants, run by Lin BioScience. The registered enrollment target is 90 participants. The trial reports 14 study locations across 12 states.
The verdict
NCT05756322, a Phase 1 study of Relapsed or Resistant Acute Leukaemias, is actively recruiting participants, sponsored by Lin BioScience.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 14
- Study locations
Study Summary
The most common types of acute leukaemia are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). AML is a heterogenous clonal disorder of haemopoietic progenitor cells and the most common and severe malignant leukemia in adults and is responsible for the highest mortality from leukemia. ALL is a neoplasm characterized by the growth of malignant lymphoblasts of the B or T lineage, leading to an inhibition of proliferation of the normal blood cell lineages. The primary objectives of this study are investigating the safety, tolerability, and the MTD of LBS-007. The secondary objectives are to assess the efficacy and to determine the pharmacokinetics (PK) of LBS-007. The exploratory objective is to study and correlate the changes in surrogate biomarkers in response to treatment.
Conditions Studied
Interventions
- DRUG LBS-007
Study Locations (14)
Other
- China Medical University Hospital - Taichung
- National Cheng Kung University Hospital - Tainan
- National Taiwan University Hospital - Taipei
Florida
- Moffitt Cancer Center - Tampa
Illinois
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University - Chicago
Kansas
- The University of Kansas Hospital - Fairway
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
North Carolina
- UNC Hospitals, The University of North Carolina at Chapel Hill - Chapel Hill
New South Wales
- Wollongong Private Hospital - Wollongong
Queensland
- Pindara Private Hospital - Benowa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-07-20 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05756322
The ClinicalTrials.gov registry entry for NCT05756322 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lin BioScience, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Resistant Acute Leukaemias appearing as the primary indexed condition, and to 1 intervention - of which LBS-007 is the first listed.
NCT05756322 reports 14 study locations spanning 12 distinct geographic areas - top geographies include Other, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05756322 about?
NCT05756322 is a clinical study titled "The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias". The most common types of acute leukaemia are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). AML is a heterogenous clonal disorder of haemopoietic progenitor cells and the most common and severe malignant leukemia in adults and is responsible for the highest mortality from leu...
What is the current status of trial NCT05756322?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2023-07-20. Estimated completion is 2026-12-31.
What conditions does trial NCT05756322 study?
This clinical trial studies the following conditions: Relapsed or Resistant Acute Leukaemias.
What interventions are being tested in trial NCT05756322?
The interventions under investigation include: LBS-007 (DRUG).
Who is sponsoring clinical trial NCT05756322?
This trial is sponsored by Lin BioScience, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05756322 being conducted?
This trial has 14 study locations across Florida, Illinois, Kansas, Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.